Ticker Details
Novavax, Inc. Novavax Inc is a clinical-stage vaccine company. It is engaged in the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants.
IPO Date:	December 13, 1995
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$1.55B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.98 | 4.13%
Avg Daily Range (30 D):	$0.33 | 3.43%
Avg Daily Range (90 D):	$0.29 | 3.03%

Institutional Daily Volume
Avg Daily Volume:	2.92M
Avg Daily Volume (30 D):	4.28M
Avg Daily Volume (90 D):	4.07M

Trade Size
Avg Trade Size (Sh.):	141
Avg Trade Size (Sh.) (30 D):	125
Avg Trade Size (Sh.) (90 D):	124

Institutional Trades
Total Institutional Trades:	9,095
Avg Institutional Trade:	$3.47M
Avg Institutional Trade (30 D):	$3.4M
Avg Institutional Trade (90 D):	$2.6M
Avg Institutional Trade Volume:	.1M
Avg Institutional Trades (Per Day):	3

Market Closing Trades
Avg Closing Trade:	$6.41M
Avg Closing Trade (30 D):	$4.85M
Avg Closing Trade (90 D):	$3.87M
Avg Closing Volume:	237.76K

News

May 13, 2026 @ 5:15 PM 3 Reasons Not to Buy Into the Hantavirus-Related B... Source: Prosper Junior Bakiny

May 8, 2026 @ 6:18 PM What's Going On With Novavax Stock On Friday? Source: Vandana Singh

Jan 29, 2026 @ 1:30 PM This Beaten-Down Biotech Is Showing Signs of Life.... Source: Prosper Junior Bakiny

Jan 26, 2026 @ 10:02 PM Stock Market Today, Jan. 20: ImmunityBio Soars Aga... Source: Josh Kohn-Lindquist

Sep 26, 2025 @ 4:08 AM Robert F. Kennedy Jr. Faces Impeachment Push From ... Source: Vishaal Sanjay

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.54	$-.06	$.11
Diluted EPS	$-.64	$-.06	$.05
Revenue	$596.34M	$139.51M	$147.14M
Gross Profit	$506.72M	$108.82M	$125.04M
Net Income / Loss	$-87.84M	$-9.49M	$17.53M
Operating Income / Loss	$-78.15M	$-15.43M	$14.23M
Cost of Revenue	$89.62M	$30.7M	$22.1M
Net Cash Flow	$-45.56M	$-23.13M	$-27.31M
PE Ratio

Splits
May 10, 2019	1:20